New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has, for the first time, quantified the impact of different aspects of childhood obesity on long-term health and life expectancy.
Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s Nipocalimab?
Nipocalimab is a monoclonal antibody commercialized by Johnson & Johnson, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia.